Asset Details
Do you wish to reserve the book?
Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma
Do you wish to request the book?
Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pretherapeutic gamma-glutamyltransferase is an independent prognostic factor for patients with renal cell carcinoma
2014
Overview
Background:
Gamma-glutamyltransferase (GGT) regulates apoptotic balance and promotes cancer progression and invasion. Higher pretherapeutic GGT serum levels have been associated with worse outcomes in various malignancies, but there are no data for renal cell carcinoma (RCC).
Methods:
Pretherapeutic GGT serum levels and clinicopathological parameters were retrospectively evaluated in 921 consecutive RCC patients treated with nephrectomy at a single institution between 1998 and 2013. Gamma-glutamyltransferase was analysed as continuous and categorical variable. Associations with RCC-specific survival were assessed with Cox proportional hazards models. Discrimination was measured with the C-index. Decision-curve analysis was used to evaluate the clinical net benefit. The median postoperative follow-up was 45 months.
Results:
Median pretherapeutic serum GGT level was 25 U l
−1
. Gamma-glutamyltransferase levels increased with advancing T (
P
<0.001), N (
P
=0.006) and M stages (
P
<0.001), higher grades (
P
<0.001), and presence of tumour necrosis (
P
<0.001). An increase of GGT by 10 U l
−1
was associated with an increase in the risk of death from RCC by 4% (HR 1.04,
P
<0.001). Based on recursive partitioning-based survival tree analysis, we defined four prognostic categories of GGT: normal low (<17.5 U l
−1
), normal high (17.5 to <34.5 U l
−1
), elevated (34.5 to <181.5 U l
−1
), and highly elevated (⩾181.5 U l
−1
). In multivariable analyses that adjusted for the effect of standard features, both continuously and categorically coded GGT were independent prognostic factors. Adding GGT to a model that included standard features increased the discrimination by 0.9% to 1.8% and improved the clinical net benefit.
Conclusions:
Pretherapeutic serum GGT is a novel and independent prognostic factor for patients with RCC. Stratifying patients into prognostic subgroups according to GGT may be used for patient counselling, tailoring surveillance, individualised treatment planning, and clinical trial design.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
/ Aged
/ Biological and medical sciences
/ Biomedical and Life Sciences
/ Carcinoma, Renal Cell - enzymology
/ Carcinoma, Renal Cell - pathology
/ Female
/ gamma-Glutamyltransferase - blood
/ Humans
/ Kidney Neoplasms - enzymology
/ Kidney Neoplasms - pathology
/ Kidneys
/ Male
/ Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
/ Nephrology. Urinary tract diseases
/ Oncology
/ Patients
/ Tumors
/ Tumors of the urinary system
/ Urology
